This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Atropine penalisation for amblyopia in the UK

Atropine penalisation for amblyopia in the UK
Reviewed by Fiona Rowe

1 June 2015 | Fiona Rowe (Prof) | EYE - Paediatrics, EYE - Strabismus

The authors aimed to determine the current clinical practice of atropine penalisation (AP) in the UK, to identify perceived barriers limiting use of AP as a first line treatment and ascertain whether any of the barriers could be resolved. An anonymised online survey was distributed through the UK professional society for orthoptists (BIOS). Responses were obtained from 151 orthoptists (13% return). Seventy-one percent indicated they had department protocols regarding the use of AP. Twenty-five percent used AP as the first line of treatment for amblyopia. Children younger than seven years were most commonly targeted. Its use was considered in more moderate to severe density of amblyopia. Eighty-nine percent would stop treatment if no improvement in visual acuity was noted over three consecutive visits. Forty-eight percent favoured daily atropine, 41% alternate day, 29% weekend use and 9% weekly use. Reported recognised side-effects included skin rash / flushing, mood changes, eye irritation / pain. Barriers to use included department-specific problems with use of AP, inability to prescribe and inability to obtain atropine. The survey showed that the percentage of orthoptists offering AP as a first line treatment has increased. It was avoided in older children because of perceived risks of intractable diplopia. Orthoptists still raise concerns regarding general efficacy, side-effects and reverse amblyopia. 

Use of atropine penalisation to treat amblyopia in UK orthoptic practice.
Piano M, Newsham D, O’Connor AR.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2014;51(6):363-9.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency